Technetium Tc-99m Sestamibi

DRUG3 trials

Sponsors

M.D. Anderson Cancer Center, Jonsson Comprehensive Cancer Center, Mayo Clinic

Conditions

Breast NeoplasmEstrogen Receptor NegativeHER2/Neu NegativeKidney NeoplasmProgesterone Receptor NegativeRenal MassTriple-Negative Breast Carcinoma

Early Phase 1

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

Active, not recruitingNCT02744053

M.D. Anderson Cancer CenterEstrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative +1

Start: 2016-11-07End: 2026-04-30Updated: 2025-10-20

Unknown Phase

SPECT/CT for the Characterization of Renal Masses

Active, not recruitingNCT03996850

Jonsson Comprehensive Cancer CenterKidney Neoplasm, Renal Mass

Start: 2018-12-07End: 2027-12-31Updated: 2026-03-13

Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities

RecruitingNCT06058650

Mayo ClinicBreast Neoplasm

Start: 2021-08-26End: 2026-08-26Target: 70Updated: 2025-09-30

Related Papers

Molecular Breast Imaging Biopsy with a Dual-Detector System

Radiology Imaging Cancer2024-06-015 citations

Assessment of Early Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer Using Amide Proton Transfer–weighted Chemical Exchange Saturation Transfer MRI: A Pilot Study

Radiology Imaging Cancer2021-09-0126 citations